エムバイオテックが、創薬ベンチャーとして、X-HUB TOKYO GLOBAL STARTUP ACCELERATOR OUTBOUND PROGRAM(X-HUB Tokyo ロンドンコース)に採択
・世界展開を目指すグローバル企業のためのプログラム
・コロナ後遺症についても、慢性化したMIDの症状とよく似ており、MIDを的確に診断する診断薬が必要
👋 MedCity and the UK delegation are now in Tokyo, ready for #BioJapan which starts on Wednesday in Yokohama.
Tomorrow the delegation will be at the UK Life Sciences Symposium, co-hosted by MedCity and Link-J.
Stay tuned for regular BioJapan updates!
https://t.co/MCv6ZQU3X0
Oxenita's Masashi Matsunaga @Biospire_Japan will be co-hosting a UK-Japan Life Science Seminar with our friends at @LINKJ20160324
We will be joined by key speakers from British Embassy (DIT @tradegovuk), Cancer Research UK @CR_UK and @MedCityHQ
https://t.co/TmNeqH5UM1